Pharmacyclics Completes Patient Enrollment in Xcytrin Phase II Clinical Trial For Primary Brain Tumors
Pharmacyclics, Inc. today announced the company has completed patient enrollment in a Phase II clinical trial to evaluate its lead investigational product, Xcytrin(R) Injection, for the potential treatment of glioblastoma multiforme, the most common primary central nervous system tumor in adults.
Aug 02 7:31 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010802/sfth023.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines